Candel Therapeutics (NASDAQ:CADL - Get Free Report) was upgraded by research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Monday, Zacks reports.
Other equities research analysts have also recently issued research reports about the company. Canaccord Genuity Group lowered their price target on Candel Therapeutics from $25.00 to $13.00 and set a "buy" rating for the company in a research note on Friday, November 13th. Jefferies Financial Group began coverage on shares of Candel Therapeutics in a research report on Thursday, October 22nd. They set a "buy" rating and a $25.00 price objective on the stock. HC Wainwright reduced their target price on shares of Candel Therapeutics from $23.00 to $18.00 and set a "buy" rating for the company in a research note on Friday, November 13th. Wall Street Zen downgraded shares of Candel Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Finally, Stifel Nicolaus decreased their target price on shares of Candel Therapeutics from $22.00 to $19.00 and set a "buy" rating for the company in a research report on Friday, November 13th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $18.29.
Read Our Latest Report on CADL
Candel Therapeutics Price Performance
CADL opened at $5.40 on Monday. The stock has a market cap of $423.63 million, a price-to-earnings ratio of -3.65 and a beta of -0.27. Candel Therapeutics has a 1 year low of $4.35 and a 1 year high of $14.00. The company has a current ratio of 7.57, a quick ratio of 7.57 and a debt-to-equity ratio of 0.37. The stock has a fifty day moving average price of $9.47 and a 200 day moving average price of $8.39.
Candel Therapeutics (NASDAQ:CADL - Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.06. Analysts forecast that Candel Therapeutics will post -1.22 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in CADL. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Candel Therapeutics in the 3rd quarter worth approximately $41,000. Legal & General Group Plc acquired a new position in Candel Therapeutics during the second quarter valued at approximately $63,000. Cetera Investment Advisers acquired a new position in Candel Therapeutics during the third quarter valued at approximately $124,000. Renaissance Technologies LLC bought a new position in shares of Candel Therapeutics in the first quarter valued at approximately $63,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Candel Therapeutics by 19.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company's stock valued at $152,000 after purchasing an additional 2,301 shares during the period. Institutional investors and hedge funds own 13.93% of the company's stock.
Key Stories Impacting Candel Therapeutics
Investors following CADL have been watching these stories:
- Neutral Sentiment: HC Wainwright maintained its Buy rating and $18 price target, while raising its FY2026 loss estimate. The target is a supportive signal, but the firm’s longer-range forecasts were cut substantially. MarketBeat analyst estimates
- Negative Sentiment: HC Wainwright lowered projected earnings for FY2027 through FY2030, including moving its FY2028 estimate from a profit to a loss. Brookline’s estimates also point to ongoing quarterly losses through 2027, reinforcing concerns about the path to profitability. MarketBeat analyst estimates
- Negative Sentiment: Law firms announced investigations and investor notices following Candel’s delay of its aglatimagene biologics license application (BLA) for prostate cancer to mid-2027. The notices allege potential securities-law issues; they are not findings of wrongdoing. The filing delay had already triggered a sharp selloff, and the legal scrutiny could add uncertainty. SBS Law investigation notice Levi and Korsinsky investigation notice
About Candel Therapeutics
(
Get Free Report)
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company's clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Candel Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Candel Therapeutics wasn't on the list.
While Candel Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.